Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 3
1(20.0%)
5Total
Phase 2(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03289299Phase 2Active Not Recruiting

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Role: lead

NCT03695744Phase 2Unknown

Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

Role: collaborator

NCT03143036Phase 2Unknown

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Role: collaborator

NCT03143049Phase 3Unknown

Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Role: collaborator

NCT03140943Phase 2Unknown

Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Role: collaborator

All 5 trials loaded